[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100620029":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":33,"centralContacts":34,"locations":41,"responsibleParty":59,"collaborators":33,"id":62,"slug":63,"hasResults":64,"nctId":65,"briefTitle":66,"officialTitle":67,"acronym":68,"eligibilityCriteria":69,"healthyVolunteers":64,"sex":70,"minAge":71,"maxAge":33,"enrollmentInfo":72,"targetDuration":33,"studyType":75,"phases":76,"briefSummary":78,"conditions":79,"keywords":81,"overallStatus":86,"whyStopped":33,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":88,"startDateStruct":91,"completionDateStruct":93,"leadSponsor":95,"locationsCount":96},{"fullName":5,"class":6},"Cairo University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Topical Diacerein","EXPERIMENTAL","Participants assigned to this arm will receive topical diacerein cream 1% applied twice daily for a treatment period of two months.",[13],"Drug: Diacerein",{"label":15,"type":16,"description":17,"interventionNames":18},"Placebo","PLACEBO_COMPARATOR","Participants assigned to this arm will receive a matching placebo topical cream applied twice daily for a treatment period of two months.",[19],"Drug: Placebo",[21,28],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","Diacerein","Topical diacerein cream 1% will be applied to affected skin areas twice daily for a treatment duration of two months.",[9],[27],"Topical diacerein",{"type":22,"name":15,"description":29,"armGroupLabels":30,"otherNames":31},"A matching placebo topical formulation will be applied to affected skin areas twice daily for a treatment duration of two months.",[15],[32],"Matching placebo topical formulation",null,[35],{"name":36,"role":37,"phone":38,"phoneExt":39,"email":40},"Alaa A Helal, BSc in Pharmacy","CONTACT","1124438381","+20","alaa.ashraf.muhammad@std.pharma.cu.edu.eg",[42],{"facility":43,"status":33,"city":44,"state":33,"zip":33,"country":45,"countryCode":46,"cosmosGeoPoint":47,"geoPoint":52,"contacts":53},"Kasr Al-Ainy Psoriasis Unit","Cairo","Egypt","EG",{"type":48,"coordinates":49},"Point",[50,51],31.24967,30.06263,{"lat":51,"lon":50},[54,57],{"name":55,"role":37,"phone":56,"phoneExt":39,"email":33},"Yousra A Azzazi, PhD, Faculty of Medicine","109 870 9984",{"name":55,"role":58,"phone":33,"phoneExt":33,"email":33},"PRINCIPAL_INVESTIGATOR",{"type":58,"investigatorFullName":60,"investigatorTitle":61,"investigatorAffiliation":5,"oldNameTitle":33,"oldOrganization":33},"Alaa Ashraf Muhammad Helal","Teaching Assistant, Clinical Pharmacy Department, Faculty of Pharmacy, Ahram Canadian University","100620029","phase-4-topical-diacerein-in-psoriasis-vulgaris-100620029",false,"NCT07352306","Topical Diacerein in Psoriasis Vulgaris","The Efficacy of Topical Diacerein Cream in Patients With Psoriasis Vulgaris","DIA","Inclusion Criteria:\n\n* Age ≥18 years old of both genders.\n* Patients with mild chronic plaque psoriasis body surface area (BSA \\\u003C 10%) along with Psoriasis Area and Severity Index (PASI) score of \\\u003C 10, and\u002For Dermatology Life Quality Index (DLQI) score of \\\u003C10.\n\nExclusion Criteria:\n\n* Documented hypersensitivity or idiosyncratic reaction to the investigational product or any excipients contained within the cream formulation.\n* Intake of anti-psoriatic systemic therapy within the last 3 months, or topical treatments within the last 2 weeks.\n* Patients with pustular psoriasis.\n* Pregnant and breast-feeding individuals.\n* Patients with psoriatic arthritis.","ALL","18 Years",{"count":73,"type":74},60,"ESTIMATED","INTERVENTIONAL",[77],"PHASE4","The goal of this clinical trial is to evaluate the safety and effectiveness of topical diacerein in adults with psoriasis vulgaris. The primary objective of the study is to compare the proportion of participants who achieve a clinically meaningful improvement in disease severity between the topical diacerein group and the placebo group.\n\nParticipants will:\n\nBe assigned to receive topical diacerein 1% or placebo twice daily for a treatment period of 2 months.\n\nAttend follow-up visits at Weeks 2, 4, 6, and 8. Undergo an additional evaluation one month after treatment cessation.",[80],"Psoriasis Vulgaris",[23,82,83,84,85],"Psoriasis vulgaris","Topical","Interleukin-1β inhibitor","Randomized controlled trial","NOT_YET_RECRUITING","2026-01-11",{"date":89,"type":90},"2026-01-20","ACTUAL",{"date":92,"type":74},"2026-02-01",{"date":94,"type":74},"2027-05-01",{"name":5,"class":6},1]